Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FORTITUDE-201 bemarituzumab in squamous non-small-cell lung cancer
jRCT2051220022Phase 1Completed
- Sponsor
- Amgen
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of bemarituzumab in non-small cell lung cancer (NSCLC) (5 arms), sponsored by Amgen. Primary endpoints: Number of participants who experienced a dose-limiting toxicity and Number of participants with treatment-emergent adverse events. Started Mar 2022; status: completed.
02
Drugs
bemarituzumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2051220022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051220022.